Article Text

Download PDFPDF

Alzheimer’s disease: differences in technetium-99m HMPAO SPECT scan findings between early onset and late onset dementia
  1. P M Kemp1,
  2. C Holmes2,
  3. S M A Hoffmann3,
  4. L Bolt3,
  5. R Holmes4,
  6. J Rowden2,
  7. J S Fleming3
  1. 1Department of Nuclear Medicine, Southampton University Hospitals Trust, Southampton, UK
  2. 2Memory Assessment and Research Centre, Moorgreen Hospital, Southampton, UK
  3. 3Department of Medical Physics and Bioengineering, Southampton University Hospitals Trust
  4. 4Department of Medical Physics and Bioengineering, Bristol Royal Infirmary, Bristol, UK
  1. Correspondence to:
 Dr P M Kemp, Department of Nuclear Medicine, Southampton University Hospitals Trust, Southampton, Hampshire, United Kingdom; 
 paul.kemp{at}suht.swest.nhs.uk

Abstract

Objective: To compare the HMPAO SPECT cerebral perfusion patterns in early and late onset Alzheimer’s disease.

Methods: Twenty patients with early onset disease (<65 years) and 44 patients with late onset disease (>65 years) were studied. All patients fulfilled NINCDS-ADRDA clinical criteria and had details of disease severity and length of history at the time of imaging. Technetium-99m HMPAO SPECT brain scans were acquired on a multi-detector gammacamera and analysed visually and with statistical parametric mapping (SPM99).

Results: Patients with early onset disease had significantly greater posterior cortical association area involvement whereas those with late onset disease had significantly greater medial temporal hypoperfusion. These findings were unchanged after controlling for disease severity and length of illness.

Discussion: These functional imaging findings of the differences between early and late onset Alzheimer’s disease are supported by published findings that include histopathological and clinical evidence; namely late onset patients tend to present with the characteristic involvement of the medial temporal lobes producing marked memory loss whereas early onset patients present with predominant posterior cortical association area involvement. These age related findings should be borne in mind when clinically diagnosing, and interpreting functional brain imaging studies in, patients with suspected Alzheimer’s disease.

  • Alzheimer’s disease
  • HMPAO
  • SPECT
View Full Text

Statistics from Altmetric.com

Footnotes

  • Competing interests: PMK has participated in European multi-centre trials and received research sponsorship from Amersham Health, manufacturer of HMPAO (Ceretec).

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.